BioCentury
ARTICLE | Financial News

Elicio raises $30M to target cancer vaccines to the lymph nodes

March 27, 2019 11:28 PM UTC

Elicio launched Wednesday with $30 million in funding and an immunotherapy strategy aimed at getting cancer vaccines into the lymph nodes, a location that orchestrates immune responses but has been hard to target directly.

Elicio Therapeutics (Cambridge, Mass.) has exclusively licensed the Amphiphile platform from Darrell Irvine at the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology. Irvine's group figured out in 2014 how to ferry cancer vaccines into lymph nodes by tethering the vaccines to albumin to “hitchhike” on the carrier's normal transportation route (see "Hitchhiker's Guide to the Lymph Node")...



Access The Full Article